PARADISE - MI
Prospective ARNI vs. ACE Inhibitor Trial to Determine Superiority in Reducing Heart Failure Events After MI
Patients with spontaneous AMI, LV systolic dysfunction and/or pulmonary congestion, and 1 out of 8 potential risk factors.
The aim of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily, in addition to conventional post-AMI treatment, in reducing the occurrence of composite endpoint of CV death, HF hospitalization and outpatient HF (time-to-first event analysis) in post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary congestion, with no known prior history of chronic HF.
Frequently asked questions (FAQ) regarding cardiac clinical research trials.
To find out if you are eligible for one of our research studies or to receive additional information contact us at (402) 384-2705.